RGNX
REGENXBIO Inc.$7.88-0.81 (-9.26%)Prev Close$8.69·MCap$441.0M·P/E—·Vol971.1K·Yield—
▲
Buys (12M)
1
$949.4K
▼
Sells (12M)
13
$5.05M
◆
Net Activity
Net Seller
$4.10M
●
Active Insiders
6
last 12 mo
Over the past 12 months, insider activity at REGENXBIO Inc. (RGNX) has been dominated by selling, with 1 insider purchase totaling $949.4K and 13 insider sales totaling $5.05M. The most recent insider transaction was by Ciongoli Gregory Austin (director), who purchased $949.4K worth of shares on Aug 27, 2026. REGENXBIO Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $441.0M.
RGNX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Ciongoli Gregory Austin | director | Buy | 102,603 | $9.25 | $949.4K | 118,035+665% |
| Jul 6, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 2,161 | $13.64 | $29.5K | 213,009 |
| Jul 1, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 56,333 | $12.23 | $688.8K | 213,009 |
| May 13, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 15,309 | $11.02 | $168.7K | 232,617 |
| Mar 12, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 5,124 | $10.35 | $53.0K | 247,926 |
| Feb 1, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 4,700 | $11.16 | $52.5K | 0 |
| Feb 1, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | 5,267 | $11.16 | $58.8K | 0 |
| Jan 27, 2026 | Mills Kenneth T. | Director | Sell | 221,753 | $13.41 | $2.97M | 0 |
| Jan 2, 2026 | Simpson Curran | Chief Executive Officer | Sell | 18,559 | $14.40 | $267.3K | 0 |
| Jan 2, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 9,793 | $14.40 | $141.0K | 0 |
| Jan 2, 2026 | Malzahn Craig | Chief Technology Officer | Sell | 1,238 | $14.40 | $17.8K | 0 |
| Jan 2, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | 18,247 | $14.40 | $262.8K | 0 |
| Oct 9, 2025 | Simpson Curran | Chief Executive Officer | Sell | 20,811 | $12.62 | $262.6K | 0 |
| Sep 29, 2025 | Simpson Curran | Chief Executive Officer | Sell | 7,624 | $10.03 | $76.5K | 0 |
| Sep 10, 2025 | Simpson Curran | Chief Executive Officer | Sell | 7,734 | $10.02 | $77.5K | 0 |
| Sep 1, 2025 | Chan Mitchell | Chief Financial Officer | Sell | 4,901 | $8.93 | $43.8K | 0 |
| Sep 1, 2025 | Malzahn Craig | Chief Technology Officer | Sell | 234 | $8.93 | $2.1K | 0 |
| Aug 1, 2025 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 4,699 | $8.19 | $38.5K | 0 |
| Jul 1, 2025 | Simpson Curran | Chief Executive Officer | Sell | 4,701 | $8.23 | $38.7K | 0 |
| May 12, 2025 | Mills Kenneth T. | Director | Sell | 20,602 | $7.91 | $163.0K | 0 |
| Feb 1, 2025 | Christmas Patrick J. | Chief Legal Officer | Sell | 4,700 | $8.07 | $37.9K | 0 |
| Feb 1, 2025 | Danos Olivier | Chief Scientific Officer | Sell | 5,452 | $8.07 | $44.0K | 0 |
| Feb 1, 2025 | PAKOLA STEVE | Chief Medical Officer | Sell | 5,263 | $8.07 | $42.5K | 0 |
| Oct 2, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $10.11 | $101.1K | 11,286-47% | |
| Sep 4, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $11.56 | $115.6K | 11,986-45% | |
| Aug 5, 2024 | KARABELAS ARGERIS N | Sell | 10,100 | $13.51 | $136.5K | 11,786-46% | |
| Aug 5, 2024 | Simpson Curran | Chief Executive Officer | Sell | 100 | $15.00 | $1.5K | 170,037 |
| Jul 30, 2024 | KARABELAS ARGERIS N | Sell | 11,000 | $15.05 | $165.5K | 11,286-49% | |
| Jul 30, 2024 | Simpson Curran | Chief Executive Officer | Sell | 9,648 | $15.04 | $145.1K | 170,137 |
| Jul 26, 2024 | Mills Kenneth T. | Sell | 27,590 | $13.88 | $382.9K | 408,035 | |
| Jul 18, 2024 | Mills Kenneth T. | Sell | 2,410 | $13.77 | $33.2K | 408,035 | |
| Jul 3, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $11.27 | $112.7K | 11,286-47% | |
| May 16, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $15.81 | $237.2K | 408,035 |
| Apr 17, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $18.19 | $272.9K | 408,035 |
| Mar 18, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $21.86 | $327.9K | 408,035 |
| Mar 7, 2024 | PAKOLA STEVE | Chief Medical Officer | Sell | 12,878 | $28.36 | $365.2K | 107,192 |
| Feb 16, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $16.76 | $251.3K | 418,383 |
| Jan 18, 2024 | Mills Kenneth T. | President and CEO | Sell | 45,000 | $15.18 | $683.0K | 408,035 |
| Jan 4, 2024 | PAKOLA STEVE | Chief Medical Officer | Sell | 17,237 | $17.39 | $299.8K | 107,192 |
| Dec 21, 2023 | Mills Kenneth T. | President and CEO | Sell | 45,000 | $19.69 | $885.8K | 355,289 |
| Jan 5, 2023 | PAKOLA STEVE | Chief Medical Officer | Sell | 3,138 | $22.17 | $69.6K | 12,175 |
| Aug 31, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 2,400 | $30.24 | $72.6K | 135,160 |
| Aug 8, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 17,680 | $35.18 | $622.0K | 154,840 |
| Aug 3, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 2,400 | $31.26 | $75.0K | 155,240 |
| Jul 15, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 4,800 | $30.01 | $144.0K | 158,108 |
| Jan 4, 2022 | PAKOLA STEVE | Chief Medical Officer | Sell | 1,598 | $33.75 | $53.9K | 8,250 |
| Dec 27, 2021 | Fox Allan M. | Sell | 112,869 | $34.69 | $3.92M | 1,581,212 | |
| Nov 10, 2021 | Mills Kenneth T. | President and CEO | Sell | 1,500 | $40.00 | $60.0K | 280,984 |
| Sep 29, 2021 | Mills Kenneth T. | President and CEO | Sell | 1,500 | $42.19 | $63.3K | 280,984 |
| Sep 21, 2021 | Fox Allan M. | Director | Sell | 48,233 | $45.04 | $2.17M | 1,364,309 |
Showing 1–50 of 52
1 / 2
RGNX Insider Buying Activity
The following table shows recent insider purchases of REGENXBIO Inc. (RGNX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 27, 2026 | Ciongoli Gregory Austin | director | Buy | 102,603 | $9.25 | $949.4K | 118,035+665% |
RGNX Insider Selling Activity
The following table shows recent insider sales of REGENXBIO Inc. (RGNX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 2,161 | $13.64 | $29.5K | 213,009 |
| Jul 1, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 56,333 | $12.23 | $688.8K | 213,009 |
| May 13, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 15,309 | $11.02 | $168.7K | 232,617 |
| Mar 12, 2026 | PAKOLA STEVE | officer: Chief Medical Officer | Sell | 5,124 | $10.35 | $53.0K | 247,926 |
| Feb 1, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 4,700 | $11.16 | $52.5K | 0 |
| Feb 1, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | 5,267 | $11.16 | $58.8K | 0 |
| Jan 27, 2026 | Mills Kenneth T. | Director | Sell | 221,753 | $13.41 | $2.97M | 0 |
| Jan 2, 2026 | Simpson Curran | Chief Executive Officer | Sell | 18,559 | $14.40 | $267.3K | 0 |
| Jan 2, 2026 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 9,793 | $14.40 | $141.0K | 0 |
| Jan 2, 2026 | Malzahn Craig | Chief Technology Officer | Sell | 1,238 | $14.40 | $17.8K | 0 |
| Jan 2, 2026 | PAKOLA STEVE | Chief Medical Officer | Sell | 18,247 | $14.40 | $262.8K | 0 |
| Oct 9, 2025 | Simpson Curran | Chief Executive Officer | Sell | 20,811 | $12.62 | $262.6K | 0 |
| Sep 29, 2025 | Simpson Curran | Chief Executive Officer | Sell | 7,624 | $10.03 | $76.5K | 0 |
| Sep 10, 2025 | Simpson Curran | Chief Executive Officer | Sell | 7,734 | $10.02 | $77.5K | 0 |
| Sep 1, 2025 | Chan Mitchell | Chief Financial Officer | Sell | 4,901 | $8.93 | $43.8K | 0 |
| Sep 1, 2025 | Malzahn Craig | Chief Technology Officer | Sell | 234 | $8.93 | $2.1K | 0 |
| Aug 1, 2025 | Christmas Patrick J. | Chief Strategy & Legal Officer | Sell | 4,699 | $8.19 | $38.5K | 0 |
| Jul 1, 2025 | Simpson Curran | Chief Executive Officer | Sell | 4,701 | $8.23 | $38.7K | 0 |
| May 12, 2025 | Mills Kenneth T. | Director | Sell | 20,602 | $7.91 | $163.0K | 0 |
| Feb 1, 2025 | Christmas Patrick J. | Chief Legal Officer | Sell | 4,700 | $8.07 | $37.9K | 0 |
| Feb 1, 2025 | Danos Olivier | Chief Scientific Officer | Sell | 5,452 | $8.07 | $44.0K | 0 |
| Feb 1, 2025 | PAKOLA STEVE | Chief Medical Officer | Sell | 5,263 | $8.07 | $42.5K | 0 |
| Oct 2, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $10.11 | $101.1K | 11,286-47% | |
| Sep 4, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $11.56 | $115.6K | 11,986-45% | |
| Aug 5, 2024 | KARABELAS ARGERIS N | Sell | 10,100 | $13.51 | $136.5K | 11,786-46% | |
| Aug 5, 2024 | Simpson Curran | Chief Executive Officer | Sell | 100 | $15.00 | $1.5K | 170,037 |
| Jul 30, 2024 | KARABELAS ARGERIS N | Sell | 11,000 | $15.05 | $165.5K | 11,286-49% | |
| Jul 30, 2024 | Simpson Curran | Chief Executive Officer | Sell | 9,648 | $15.04 | $145.1K | 170,137 |
| Jul 26, 2024 | Mills Kenneth T. | Sell | 27,590 | $13.88 | $382.9K | 408,035 | |
| Jul 18, 2024 | Mills Kenneth T. | Sell | 2,410 | $13.77 | $33.2K | 408,035 | |
| Jul 3, 2024 | KARABELAS ARGERIS N | Sell | 10,000 | $11.27 | $112.7K | 11,286-47% | |
| May 16, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $15.81 | $237.2K | 408,035 |
| Apr 17, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $18.19 | $272.9K | 408,035 |
| Mar 18, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $21.86 | $327.9K | 408,035 |
| Mar 7, 2024 | PAKOLA STEVE | Chief Medical Officer | Sell | 12,878 | $28.36 | $365.2K | 107,192 |
| Feb 16, 2024 | Mills Kenneth T. | President and CEO | Sell | 15,000 | $16.76 | $251.3K | 418,383 |
| Jan 18, 2024 | Mills Kenneth T. | President and CEO | Sell | 45,000 | $15.18 | $683.0K | 408,035 |
| Jan 4, 2024 | PAKOLA STEVE | Chief Medical Officer | Sell | 17,237 | $17.39 | $299.8K | 107,192 |
| Dec 21, 2023 | Mills Kenneth T. | President and CEO | Sell | 45,000 | $19.69 | $885.8K | 355,289 |
| Jan 5, 2023 | PAKOLA STEVE | Chief Medical Officer | Sell | 3,138 | $22.17 | $69.6K | 12,175 |
| Aug 31, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 2,400 | $30.24 | $72.6K | 135,160 |
| Aug 8, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 17,680 | $35.18 | $622.0K | 154,840 |
| Aug 3, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 2,400 | $31.26 | $75.0K | 155,240 |
| Jul 15, 2022 | Vasista Vittal | Chief Financial Officer | Sell | 4,800 | $30.01 | $144.0K | 158,108 |
| Jan 4, 2022 | PAKOLA STEVE | Chief Medical Officer | Sell | 1,598 | $33.75 | $53.9K | 8,250 |
| Dec 27, 2021 | Fox Allan M. | Sell | 112,869 | $34.69 | $3.92M | 1,581,212 | |
| Nov 10, 2021 | Mills Kenneth T. | President and CEO | Sell | 1,500 | $40.00 | $60.0K | 280,984 |
| Sep 29, 2021 | Mills Kenneth T. | President and CEO | Sell | 1,500 | $42.19 | $63.3K | 280,984 |
| Sep 21, 2021 | Fox Allan M. | Director | Sell | 48,233 | $45.04 | $2.17M | 1,364,309 |
RGNX Insiders
Similar Stocks to RGNX
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B